Print

Mail

wiki links

Editorial: Biotech requires long-term view

The nation's long-time quest to boost its international standing in the biotechnology sector was partially rewarded last week with the government's announcement that it would invest US$20 million in a new biotech company that will focus on developing AIDS drugs, hepatitis vaccines and bird flu vaccines.

TaiMed Biologics Co is expected to bring a new AIDS drug, TNX-355, to the market in three years, which would make it the first drug to be produced and marketed globally by a Taiwanese company.

TNX-355 is a humanized monoclonal antibody that can prevent HIV from breaching immune system cells. It was first developed by the US pharmaceutical firm Tanox. Genentech acquired the patent following a merger earlier this year.

TaiMed Biologics secured authorization to use the patented antibody from Genentech and will conduct a second clinical trial of the drug later this year in the US, Europe and South America to evaluate its safety and efficacy.

At issue is an ambitious investment for a private biotech start-up that has obtained massive funding from the state-owned National Development Fund in return for a stake of 40 percent in the company, and which is planning to raise US$50 million in capital globally.

Nearly as remarkable as the investment itself is the company's management line-up, which includes former vice premier Tsai Ing-wen (蔡英文) as its chairwoman, AIDS researchers David Ho(何大一) as one of the founders, and Academia Sinica President Wong Chi-huey (翁啟惠) and Nobel laureate Lee Yuan-tseh (李遠哲) as board members. Impressive, sure. But does the company have a bright future?

No one can say for sure whether TaiMed Biologics will be profitable, because companies that intend to market a new drug must go through a complex, time-consuming and very expensive process.

On a positive note, the legislative passage of the Biotech and New Pharmaceutical Development Act (生技新藥產業發展條例) in June set into motion the government's determination to develop the biotech sector into a trillion dollar industry.

The issue facing the government and investors is how to position TaiMed Biologics and how they will view similar local firms, if the nation aims to gain international recognition in the biotech sector.

A high level of education, a good health care system and quality medical research give Taiwan an edge in biotech development, but the nation lacks good support from a well-developed investment environment where efficient bureaucracy, committed enterprises and a sufficient pool of legal and financial professionals are crucial and interdependent.

But a more important issue is how Taiwan sees itself in the biotech supply chain: Is it a research-oriented participant or a end-product manufacturer?

Should our biotech firms focus on buying rights to promising drugs developed overseas that have a potential to become profitable? Or should the sector focus on making compounds based on customers' designs -- the way Taiwan Semiconductor Manufacturing Co does in the chip industry or Quanta Computer in the PC industry.

This would be a short-term option that would give local companies the experience they need by studying partly developed products and conducting clinical trials on a contract basis.

But in the long run, for Taiwan to really gain international visibility, it must have local biotech companies that are capable of developing new compounds in local laboratories and taking them through the clinical trial and regulatory approval stages. That will be very expensive. Does the government -- or local industry -- really have the deep pockets or the determination necessary to see this happen?
This story has been viewed 1831 times.